Advertisement

Pharmacy World and Science

, Volume 27, Issue 3, pp 243–248 | Cite as

Cost-Effectiveness of Thrombolytics: A Simplified Model

  • Şule Apikoğlu Rabuş
  • Fikret Vehbi lzzettinEmail author
  • Mesut Sancar
  • Murat Bülent Rabuş
  • Cevat Kırma
  • Cevat Yakut
Research Article

Abstract

Objective of the study: To construct a simple model for an internal, retrospective cost-effectiveness analysis and to calculate the incremental cost-effectiveness of tissue plasminogen activator (TPA) over streptokinase (SK) in Turkey.

Setting: Koşuyolu Heart, Education and Research Hospital, Istanbul, Turkey.

Method: Among patients who were hospitalized for treatment of acute myocardial infarction (AMI), 196 were randomly selected. One-year mortality rates according to the treatment groups (TPA, SK, other) were determined. Among surviving patients, 28 from TPA and another 28 from SK group were randomly selected for the pharmacoeconomic analysis. Patient treatment data were taken from medical records while data regarding to costs were taken from hospital bills.

Main outcome measures: Incremental cost-effectiveness ratio (ICER). The cost part of the ratio was considered as ‘the overall-costs’, while the effectiveness part was considered as ‘lives saved’ per treatment group.

Results: With an increased one-year survival rate of 2.37% and an increased cost of €1120.8 ($1165.6) per patient in the TPA group, the ICER for the use of TPA instead of SK was €47,289 ($49,180.6) per life saved.

Conclusion: This model can be a guide for similar analyses. The results of our study (the incremental cost-effectiveness of TPA over SK) will be informative for the decision-makers in Turkey, by whom the medical benefit for money spent would be assessed and judged. We believe that our results make a contribution to similar studies in the literature.

Keywords

Incremental cost-effectiveness Pharmacoeconomic model Sensitivity analysis Streptokinase Thrombolytics Tissue plasminogen activator Turkey 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mark, DB, Hlatky, MA, Califf, RM,  et al. 1995Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarctionN Engl J Med332141824CrossRefPubMedGoogle Scholar
  2. Goel, V, Naylor, CD. 1992Potential cost-effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarctionCan J Cardiol8318PubMedGoogle Scholar
  3. Simoons, ML, Vos, J, Martens, LL. 1991Cost-utility analysis of thrombolytic therapyEur Heart J126949PubMedGoogle Scholar
  4. Pelc, A, Dardenne, J, Frelon, JH,  et al. 1997Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French settingPharmacoeconomics11595605PubMedGoogle Scholar
  5. Lorenzoni, R, Pagano, D, Mazzotta, G,  et al. 1998Pitfalls in the economic evaluation of thrombolysis in myocardial infarction: the impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroupsEur Heart J19151824CrossRefPubMedGoogle Scholar
  6. Tavazzi, L. 1999Clinical epidemiology of acute myocardial infarctionAm Heart J138S48S54PubMedGoogle Scholar
  7. The Thrombolysis Early in Acute Heart Attack Trial Study Group.1990Very early thrombolytic therapy in suspected acute myocardial infarctionAm J Cardiol654017Google Scholar
  8. Simoons, ML, Vos, J, Tijssen, JGP. 1989Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the NetherlandsJ Am Coll Cardiol14160915PubMedGoogle Scholar
  9. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.1994Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsLancet34331122Google Scholar
  10. Vande Werf, F. 1999What do new lytics add to t-PA?Am Heart J138S115S20PubMedGoogle Scholar
  11. Basskin, LE. 1998Practical PharmacoeconomicsAdvanstarIndianapolisGoogle Scholar
  12. T.R. Prime Ministry-State Planning Organization. Long-Term Strategy and Eight Five-Year Development Plan 2001–2005. Ankara: 2001Google Scholar
  13. Laffel, GL, Fineberg, HV, Braunwald, E,  et al. 1987A cost-effectiveness model for coronary thrombolysis/reperfusion therapyJ Am Coll Cardiol1079B90BPubMedGoogle Scholar
  14. Levin, LA, Jönsson, B. 1992Cost-effectiveness of thrombolysis-a randomized study of intravenous rt-PA in suspected myocardial infarctionEur Heart J1328Google Scholar
  15. Simoons, ML, Vas, J, Tijssen, JGP,  et al. 1989Long term benefit of early thrombolytic therapy in patients with acute myocardial infarctionJ Am Coll Cardiol14160915PubMedGoogle Scholar
  16. Califf, RM, White, HD, Werf, F,  et al. 1996One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) TrialCirculation9412338PubMedGoogle Scholar
  17. Wilcox, RG, Lippe, G, Olsson, CG,  et al. 1990Effects of alteplase in acute myocardial infarction: 6-month result from the ASSET Study – Anglo-Scandinavian Study of Early ThrombolysisLancet33511758PubMedGoogle Scholar
  18. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico.1987Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI studyLancet28714Google Scholar
  19. Baigent, C, Collins, R, fortheISIS Collaborative, Group. 1993ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarctionCirculation881291Google Scholar
  20. Naylor CD, Bronskill S, Goel V. (1992). Reprint of ‘Canadian Consensus Conference on Coronary Thrombolysis’ – Part IV: EconomicsGoogle Scholar
  21. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.1992ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarctionLancet33975370Google Scholar
  22. The Gusto Investigators.1993An international randomized trial comparing four thrombolytic strategies for acute myocardial infarctionN Engl J Med32967382Google Scholar
  23. Farkouh, M, D, U, Sackett, DL. 1994Thrombolytic agents: the science of the art of choosing the better treatmentAnn Intern Med1208868PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Şule Apikoğlu Rabuş
    • 1
  • Fikret Vehbi lzzettin
    • 1
    Email author
  • Mesut Sancar
    • 1
  • Murat Bülent Rabuş
    • 2
  • Cevat Kırma
    • 3
  • Cevat Yakut
    • 2
  1. 1.Clinical Pharmacy Department, Faculty of PharmacyMarmara UniversityIstanbulTurkey
  2. 2.Cardiovascular Surgery DepartmentKoşuyolu Heart, Education and Research HospitalIstanbulTurkey
  3. 3.Cardiology DepartmentKoşuyolu Heart, Education and Research HospitalIstanbulTurkey

Personalised recommendations